Dysferlin: Approaches to Domain Analysis and Gene Therapy
Dysferlin: Approaches to Domain Analysis and Gene Therapy
批准号:
7802951
负责人:
Robert H. Brown
金额:
$33.57万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
未结题
起止时间:
2001-09-25 至
关键词:
AnnexinsBindingBinding ProteinsBiochemicalBiologicalCalciumCell SurvivalDYSF geneDataGene Expression ProfileGenesGoalsHomologous GeneHumanLengthLimb-Girdle Muscular DystrophiesMembraneMethodsModelingMolecular BiologyMuscleMuscle CellsMuscle ProteinsMuscular DystrophiesMutationMyopathyPathogenesisPathway interactionsPhenotypePhospholipidsProcessPropertyProteinsReportingRoleSkeletal MuscleStructureTechniquesTransgenic MiceVesicleViral GenesZebrafishcell typegene therapyin vivoinjuredinsightminiaturizeprotein functionrepairedresearch study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Membrane repair is a fundamental cell survival process in large, irreplaceable, or frequently injured cell types
such as muscle cells. We have reported that the skeletal muscle protein dysferlin is defective in Miyoshi
myopathy (MM) and limb girdle muscular dystrophy type 2B (LGMD2B) and that dysferlin accelerates muscle
membrane repair via a calcium-triggered mechanism that invokes binding to annexins and the formation of
intracellar vesicular aggregates. It thus seems likely that MM and LGMD2B are a consequence of aberrant
skeletal muscle membrane repair. We now propose to define domains of dysferlin that are critical for this
repair process and determine whether truncated forms of "mini-dysferlin" can rescue the MM/LGMD2B
phenotype. Our study has five Specific Aims: (1) Generate and characterize transgenic mice that over-
express full-length and truncated dysferlin. Hypothesis: expression of supra-normal levels of full-length or
truncated dysferlin can rescue the dystrophic phenotype in a dysferlin-deficient model. (2) Characterize the
biochemical properties of truncated dysferlin. Hypothesis: A biochemical analysis of full-length and truncated
dysferlin proteins will identify domains retaining functional properties of the full-length protein. (3)
Characterize membrane repair by mini-dysferlin proteins. Hypothesis: mini-dysferlin proteins retaining
functional domains will augment membrane repair in dysferlin-deficient muscle cells. (4) Intravenously deliver
candidate AAV8-packaged mini-dysferlin genes. Hypothesis: systemic delivery of mini-dysferlin genes will
give rise to dissemination of these genes in muscle and enhanced membrane repair. (5) Analyze zebrafish
for the presence of dysferlin and for phenotypes when dysferlin homologues are down-regulated.
Hypothesis: Dysferlin-deficiency will produce a myopathic phenotype in zebrafish and it will be possible to
analyze the impact of replacement of partial or full forms of dysferlin in the zebrafish. Methods: We will use
a variety of techniques to define functional domains of dysferlin and will then analyze the rescue of the
dysferlin-deficient phenotypes by full length and truncated dysferlin delivered to muscle in vivo via transgenic
mice and systemically administered AAV8. Significance: This study willl (1) enhance our understanding of
the molecular biology of sarcolemmal membrane repair in skeletal muscle; (2) provide insight into the
functional domains of dysferlin; (3) determine the feasibility of developing mini-dysferlins for rescue of
muscle phenotypes resulting from dysferlin deficiency; and (4) develop pilot data on the efficacy of
systemically administered viral gene therapy for MM and LGMD2B.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:10599901
-
项目类别:
-
资助金额:$63.51万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:9765950
-
项目类别:
-
资助金额:$66.04万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:10374767
-
项目类别:
-
资助金额:$63.51万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:9924676
-
项目类别:
-
资助金额:$63.51万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:8767751
-
项目类别:
-
资助金额:$37.74万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:9042441
-
项目类别:
-
资助金额:$36.05万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:8853963
-
项目类别:
-
资助金额:$36.05万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:9267549
-
项目类别:
-
资助金额:$46.41万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8500486
-
项目类别:
-
资助金额:$47.9万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8348533
-
项目类别:
-
资助金额:$53.91万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8640222
-
项目类别:
-
资助金额:$48.58万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8830481
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
Transgenic Mouse Models of FUS/TLS-Mediated Amyotrophic Lateral Sclerosis
-
批准号:7821236
-
项目类别:
-
资助金额:$49.99万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
Transgenic Mouse Models of FUS/TLS-Mediated Amyotrophic Lateral Sclerosis
-
批准号:7937835
-
项目类别:
-
资助金额:$49.97万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
Full Human Genome Sequencing in ALS
-
批准号:7855558
-
项目类别:
-
资助金额:$180.44万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
Full Human Genome Sequencing in ALS
-
批准号:7939625
-
项目类别:
-
资助金额:$180.39万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
CLINICAL TRIAL: PYRIMETHAMINE FOR TREATMENT OF SOD1 MEDIATED AMYLOTROPHIC LATERA
-
批准号:7731272
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2008
-
负责人:Robert H. Brown
-
依托单位:
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
-
批准号:7944010
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2007
-
负责人:Robert H. Brown
-
依托单位:
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
-
批准号:7488977
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2007
-
负责人:Robert H. Brown
-
依托单位:
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
-
批准号:7208427
-
项目类别:
-
资助金额:$76.09万
-
财政年份:2007
-
负责人:Robert H. Brown
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: